Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | PPP5C | P53041 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22645131 | 0.77 | ADRB2 (0.39) | GBA1SMN1; SMN2ADRB2ADRB1ADRB3 | |
| SCHEMBL10705341 | 0.74 | SMN1; SMN2 (0.31) | GBA1SMN1; SMN2ADRB2ADRB1ADRB3 | |
| SCHEMBL17931096 | 0.70 | GBA1 (0.33) | GBA1 | |
| SCHEMBL16817849 | 0.68 | GBA1 (0.38) | GBA1TSHR | |
| SCHEMBL16711496 | 0.68 | GBA1 (0.38) | GBA1SMN1; SMN2ADRB2ADRB1ADRB3 | |
| SCHEMBL12590723 | 0.67 | SMN1; SMN2 (0.33) | SMN1; SMN2TSHR | |
| SCHEMBL19599988 | 0.67 | ADRB2 (0.33) | GBA1ADRB2ADRB1ADRB3PPP5C | |
| SCHEMBL4915956 | 0.67 | — | — | |
| SCHEMBL19599990 | 0.66 | NPC1 (0.36) | PPP5C | |
| SCHEMBL20787019 | 0.65 | ADRB2 (0.39) | GBA1SMN1; SMN2ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-2931708-B1 | CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF | DIVERCHIM (FR) | 2017-05-10 | — | — | EP | disclosed |
| US-9527798-B2 | Cyclopropylboronic compounds, preparation process thereof and use thereof | DIVERCHIM (FR) | 2016-12-27 | — | — | US | disclosed |
| US-20150329566-A1 | CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF | DIVERCHIM (FR) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329566-A1 | CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF | HMBS, MMAB, FDPS | GBA1 138/4885SMN1; SMN2 2991/4885ADRB2 2955/4885 |
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | TLR7, MALT1, PNPO | GBA1 446/4885SMN1; SMN2 2923/4885ADRB2 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.